AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Canadian penny stocks to buy right now. On November 7, Stifel Nicolaus reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL) and set a $7 price target. AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss A stethoscope. Photo by Pixabay The positive stance comes on the heels of the company reporting a wider-than-expected net loss of $57.1 million in its third quarter, compared to a net loss of $51.1 million ...